Subscribe To
BBI / Brickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm Sweating
BBI News
By Pulse2
July 1, 2022
Brickell Biotech (BBI) Stock: 1-For-45 Reverse Split Announced
Brickell Biotech, Inc. (Nasdaq: BBI) announced a 1-for-45 reverse split. These are the details. more_horizontal
By InvestorPlace
June 29, 2022
Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting
Delistings are commonplace in this bear market, however investors in Brickell Biotech and BBI stock are cheering some news today. The post Brickell Bi more_horizontal
By GlobeNewsWire
May 5, 2022
Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022
BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmace more_horizontal
By Benzinga
May 4, 2022
Brickell Biotech Shares Surge After Offloading Late-Stage Asset To Australia-Based Firm
Brickell Biotech Inc (NASDAQ: BBI) agreed to sell sofpironium bromide rights to Australia-based Botanix Pharmaceuticals Limited. Brickell will rec more_horizontal
By Seeking Alpha
March 15, 2022
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q4 2021 Results - Earnings Call Transcript
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Zacks Investment Research
March 15, 2022
Brickell (BBI) Reports Q4 Loss, Misses Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of 33.33% and 49.52%, respectively, for the quarter ended December 2021. Do the numbers hold c more_horizontal
By Benzinga
October 7, 2021
Brickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm Sweating
Brickell Biotech Inc (NASDAQ: BBI) has announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironiu more_horizontal
By Benzinga
October 7, 2021
Brickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm Sweating
Brickell Biotech Inc (NASDAQ: BBI) has announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironiu more_horizontal